OBJECTIVES

: Insulin lispro 100 units /mL Junior KwikPen (JrKwikPen) is a disposable pre-filled pen that delivers 0.5–30 units (U) in increments of 0.5 U, which allows for more accurate insulin dose adjustment and more precise glycaemic control. This study describes sociodemographic, clinical, and treatment characteristics of patients with diabetes who initiated treatment with JrKwikPen in real world practice in Spain.

METHODS

: This observational retrospective study, based on IQVIA’s electronic medical records databases, included patients of all ages with type 1 diabetes (T1D) or type 2 diabetes (T2D) who started treatment with JrKwikPen between 1^st May 2018 and 31^st December 2020. Patient characteristics and concomitant treatment at JrKwikPen initiation (index date) and prior medical/treatment history were analysed descriptively by type of diabetes and age groups.

RESULTS

: A total of 416 patients were included. Main characteristics for T1D/T2D groups (N=326/90) were, respectively: female, 61.7%/65.6%; mean age (standard deviation [SD]), 32.5 (20.7)/55.5 (16.6) years; time since first diabetes record, 5.8 (5.1)/7.9 (4.2) years; body mass index (BMI), 20.8 (4.2)/24.8 (4.8) kg/m² (N=106/44); haemoglobin A1c (HbA1c), 8.2 (2.0)%/8.0 (1.4)% (N=67/38); presence of diabetes-associated comorbidities, 27.9%/64.4%. Only 32.8% of patients with T1D were <18 years. Among JrKwikPen users 12.3% (T1D/T2D, 6%/6.3%) were ≥65 years, 20.9% patients were newly diagnosed, and 3.8% were pregnant women. The mean (SD) total insulin dose pre-index for T1D/T2D was 42.4 (23.4)/40.7 (21.6) U/day, respectively. The mean (SD) insulin dose at initiation of JrKwikPen was 26.6 (16.6) and 22.6 (13.6) U/day for T1D/T2D, respectively. JrKwikPen was first prescribed mainly by endocrinologists (58.7%) or pediatricians (22.6%).

CONCLUSIONS

: This is the first study that describes the profile of patients treated with insulin lispro 100 U/mL JrKwikPen in clinical practice in Spain. JrKwikPen users were mainly women, adults, with T1D, low BMI, and more associated comorbidities.